Review top news and interview highlights from the week ending April 12, 2024.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The 2-part, multicenter BCT-006-US trial will seek to enroll patients who are in the earlier stages of ALS.
The postdoctoral scholar at University of California – Irvine discussed further questions he is continuing to investigate.
The cells showed activity toward PDAC cells as well as cancer-associated fibroblasts, which may address challenges with the tumor microenvironment.
The stem cell transplantation physician at the Dana-Farber Cancer Institute discussed how to look at the value therapies provide and how to improve the cost-effectiveness of their use.
AURN001 consists of allogeneic human corneal endothelial cells referred to as “neltependocel” and Y-27632, a small molecule drug.
Will the CMS CGT Model Support Patient Access to Sickle Cell Disease CGTs?
July 25th 2024Cell and gene therapies can transform the paradigm of care for patients with chronic, complex conditions, but these therapies come at an up-front cost of several million dollars per treatment, complicating the pipeline of access to them.